The first effortless continuous molecular tracker unlocking human perfomance
SAVA has raised $8.0M in total funding. The most recent round was Seed. The last funding was announced in June 2024.
SAVA's investors include Balderton Capital, SOSV, Exceptional Ventures, Exor Ventures, Social Starts.
SAVA is headquartered in London, United Kingdom.
The first effortless continuous molecular tracker unlocking human perfomance
SAVA is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SAVA — Funding & Investors." VCBacked, June 21, 2024, https://www.vcbacked.co/company/sava. Accessed September 2, 2026.
VCBacked. (2024). SAVA — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/sava
{{cite web |title=SAVA — Funding & Investors |url=https://www.vcbacked.co/company/sava |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated